STANDARD BIOTOOLS INC.·4

Jun 23, 5:39 PM ET

HIBBS KATHY L 4

Research Summary

AI-generated summary

Updated

Standard BioTools (LAB) Director Kathy Hibbs Receives RSU/Option Awards

What Happened
Kathy L. Hibbs, a director of Standard BioTools, was granted a total of 275,039 equity awards on June 18, 2026: 99,116 restricted stock units (RSUs) reported at $0.00 and 175,923 shares reported as a derivative award (also $0.00). These are awards/grants (Form 4 code A) rather than open-market purchases or sales.

Key Details

  • Transaction date: June 18, 2026; Form 4 filed June 23, 2026. Reported price per share: $0.00 (award).
  • Award totals: 99,116 RSUs + 175,923 derivative awards = 275,039 total equity units.
  • Footnote F1: The 99,116 RSUs vest in full on the earlier of June 18, 2027 or one day before the company’s next annual meeting, subject to continued service; each RSU converts to one share upon vesting.
  • Footnote F2: The derivative award is an option that becomes exercisable in 12 equal monthly installments beginning July 18, 2026, subject to continued service.
  • Shares owned after the transaction: not specified in the provided filing excerpt.
  • No sale or cash exercise was reported — these are grants, not dispositions.

Context
RSU and option grants are common compensation for directors and reflect compensation policy rather than an immediate trading view. RSUs convert to shares only upon vesting; options must be exercised to become shares. Because no purchase or sale occurred, this filing does not directly signal buying or selling intent. Investors wanting more detail should review the full Form 4 and any company disclosures (e.g., proxy statements or press releases) for grant rationale and total beneficial ownership.